RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Preclinical Studies — RedHill Biopharma Ltd.

Event summary

RedHill's Opaganib demonstrated enhanced efficacy in combination with chemotherapy for high-risk neuroblastoma and augmented anti-tumor immunity in triple-negative breast cancer (TNBC) in preclinical studies presented at AACR 2026.
Opaganib destabilized n-Myc, a key oncogenic driver in neuroblastoma, through increased ceramide production enhancing apoptosis in cancer cells.
Pre-treatment with Opaganib followed by low-dose diABZI treatment potentiated STING-mediated effects, potentially improving outcomes for TNBC, which has the poorest prognosis among breast cancer subtypes.
Opaganib received FDA Orphan Drug and Rare Pediatric Disease designations for neuroblastoma, with ongoing development discussions with Penn State University and the Beat Childhood Cancer consortium.

The big picture

RedHill's Opaganib is positioning itself as a versatile therapeutic candidate in oncology, with preclinical data suggesting it could enhance existing treatments for neuroblastoma and TNBC. The drug's broad-acting mechanism and multiple indications under development align with the growing trend of targeted therapies that address unmet needs in rare and aggressive cancers. Success in these areas could significantly boost RedHill's pipeline value and strategic partnerships.

What we're watching

Clinical Translation: Whether the preclinical findings for Opaganib in neuroblastoma and TNBC will translate into clinical success, particularly given its Orphan Drug designation and potential for a Rare Pediatric Disease Priority Review Voucher.
Combination Therapy Potential: The pace at which RedHill can advance Opaganib in combination therapies across multiple oncology indications, leveraging ongoing Phase 2 studies in prostate cancer and other potential applications.
Regulatory Pathway: How the FDA's review of Opaganib's development plans will impact its regulatory pathway, especially with the potential for a Rare Pediatric Disease Priority Review Voucher accelerating approval processes.